文献速递基础与转化研究临床试验与 GCP新药、器械与细胞基因治疗研发

双靶点CAR-T细胞治疗为高致敏肾移植候选人脱敏

Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy.
PubMed 文献 · N Engl J Med · 2026-01-01

高致敏(cPRA≥99.9%)是肾移植的重大障碍,传统脱敏疗效不稳定。该多中心1期研究安全性导入队列评估CD19与BCMA双靶点CAR-T清除抗HLA抗体细胞来源的安全性和有效性,两例高致敏候选人在双CAR-T脱敏后成功接受肾移植。

要点

  • 双靶点CAR-T旨在清除产生抗HLA抗体的细胞来源。
  • 两例cPRA≥99.9%候选人在脱敏后接受肾移植。
  • 此为1期研究安全性导入队列的初步结果。

核心结论

  • 双靶点CAR-T脱敏后,两例高致敏候选人成功接受肾移植。

研究设计与样本

  • 多中心1期临床研究的安全性导入队列(NCT06056102)。
  • 评估CD19与BCMA双靶点CAR-T清除预存抗HLA抗体细胞来源的安全性和有效性。

主要发现

  • 两例高致敏候选人在双CAR-T脱敏后接受肾移植。

关键数值与推荐

  • 纳入最高致敏水平者,定义为cPRA评分≥99.9%。

临床怎么用

  • 为传统脱敏疗效不佳的最高致敏肾移植候选人提供新的脱敏策略探索。

局限性

  • 仅为安全性导入队列,样本量小,疗效需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

HLA sensitization poses a major challenge to kidney transplantation for patients with end-stage kidney disease, especially for highly sensitized candidates. Attempts at antibody elimination (desensitization) have had inconsistent efficacy and have often failed to produce sustained reductions in anti-HLA antibodies in patients with the highest level of sensitization (calculated panel-reactive antibody score, ≥99.9%). We now report the results for the safety run-in cohort of a multicenter phase 1 clinical study evaluating the safety and efficacy of combined CD19-targeted and B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cells in eliminating the cellular sources of preformed anti-HLA antibodies (ClinicalTrials.gov number, NCT06056102). Kidney transplantation was performed in two highly sensitized candidates after desensitization with the use of dual CAR T-cell therapy.

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Bhoj VG, Kaminski M, Zhao H, et al. Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy. N Engl J Med. 2026. PMID: 42235014. doi:10.1056/NEJMoa2513428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。